Tahoe Therapeutics provides AI-powered models of the human cell that generate large-scale, perturbative single-cell datasets to inform drug design. The company’s platform aims to enable a new generation of biological foundation models for drug discovery. Tahoe plans to generate one billion single-cell datapoints, mapping how tens of thousands of drug molecules interact with human biology. It intends to use the new funding to advance its therapeutic programs toward the clinic and to launch a new model of strategic collaboration. Led by CEO Nima Alidoust, Tahoe was founded by a team of scientists and technologists advancing drug discovery, genomics, and machine learning. The company is based in South San Francisco. Vevo Therapeutics develops an in vivo drug-discovery platform, Mosaic, that combines scalable in vivo data generation with AI models to identify drugs for more patients. The platform captures in vivo disease context at single-cell precision and aims to better represent patient diversity versus current in vitro assays. Mosaic builds on technology developed by co-founders Hani Goodarzi and Johnny Yu and is exclusively licensed from UCSF Innovation Ventures. The company is led by CEO and co-founder Nima Alidoust, Ph.D., alongside co-founder Kevan Shokat, Ph.D. Vevo plans to use recent financing to accelerate growth and expand operations. The company is based in San Francisco, CA.

Total raised

$42M

Funding rounds

2

Latest round

Equity

Latest activity

Aug 2025